Belite Bio, Inc BLTE
156.52 USD -1.17 (-0.74%)
At closeNov 10, 2026, 4:00 PM EST
156.52 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
153.75 Day range 160.99
102.00 52-week range 200.00
- YTD
- -2.15%
- 1 year
- +33.39%
News
globenewswire.com Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
benzinga.com Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19 Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
globenewswire.com Belite Bio Announces Uplisting to the Nasdaq Global Select Market SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
benzinga.com Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1 Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
globenewswire.com Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
globenewswire.com Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
globenewswire.com Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
defenseworld.net Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC Squarepoint Ops LLC reduced its position in shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE) by 48.3% in the undefined quarter, according to the company in its most recent 13F filing with the…
seekingalpha.com Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
zacks.com Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross Belite Bio, Inc. Sponsored ADR (BLTE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, BLTE's 50-day simple moving average broke out…- benzinga.com Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234 Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.
benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.- benzinga.com Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1 Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and…
globenewswire.com Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
benzinga.com Why Is Belite Bio Stock Soaring Friday? Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant.
benzinga.com Why Is Belite Bio Stock Soaring Friday? Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
benzinga.com This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
247wallst.com Here Are Friday’s Top Wall Street Analyst Research Calls: Ambarella, Cal-Maine Foods, Lennar, Ormat Technologies, Paychex, PulteGroup, Shell plc, TotalEnergies, W.P. Carey, and More Wall Street wrapped a turbulent week with a wave of upgrades and downgrades hitting energy giants, homebuilders, and tech names just ahead of the Labor Day weekend. Find out which stocks analysts are…
benzinga.com Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303 Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
marketbeat.com Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority…
seekingalpha.com Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript
globenewswire.com Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
globenewswire.com Belite Bio to Host Virtual Commercial Day on September 2, 2026 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
globenewswire.com Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
benzinga.com Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206 Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.
benzinga.com Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270 Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
seekingalpha.com Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
marketbeat.com Belite Bio Q2 Earnings Call Highlights Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the…
benzinga.com Full Transcript: Belite Bio Q2 2026 Earnings Call Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…- benzinga.com Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.79) by 31.65 percent. This is a 8 percent decrease over losses of $(0.50) per…
globenewswire.com Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
zacks.com BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
benzinga.com CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $200 to $214.
benzinga.com Why Is Belite Bio Stock Gaining Monday? Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.
benzinga.com Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growthPresentation to…
benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
benzinga.com Full Transcript: Belite Bio Q1 2026 Earnings Call - benzinga.com Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215 Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.
benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
benzinga.com Earnings Scheduled For May 20, 2026 - benzinga.com Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
- benzinga.com Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have…
- benzinga.com Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
- benzinga.com Belite Bio Initiates Rolling Submission Of New Drug Application To FDA For Tinlarebant Oral Therapy To Treat Stargardt Disease Type 1 Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $200 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $185 to $200.
- benzinga.com Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $201 Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $191 to $201.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $266 Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $200 to $266.